Skip to content

RNTX RNTX Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
38.8%+7.3pp
Gilead Sciences logo
Gilead SciencesGILD
43.2%+10.7pp
AbbVie logo
AbbVieABBV
89%+32.7pp
CTO
Citius Oncology, Inc.CTOR
-119.9%+46.7pp
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
-105.3%+50.6pp
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
8.2%+4.2pp

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Calculated from RNTX’s reported figures.

Based on trailing twelve months.

The official record: RNTX’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's return on equity?
RNTX (RNTX) reported return on equity of -123.3% in Q4 2023.
How has RNTX's return on equity changed year-over-year?
RNTX's return on equity decreased by 41.1% year-over-year, from -87.4% to -123.3%.
What is the long-term trend for RNTX's return on equity?
Over 3 years (2020 to 2023), RNTX's return on equity has grown at a -6.2% compound annual growth rate (CAGR), from -149.5% to -123.3%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.